Evidence map›Paper›PMID 18665170›Full record

ArticleBritish journal of cancer2008

[18F]FDG and [18F]FLT uptake in human breast cancer cells in relation to the effects of chemotherapy: an in vitro study.

W G E Direcks, S C Berndsen, N Proost, G J Peters, J Balzarini, M D Spreeuwenberg, A A Lammertsma, C F M Molthoff

Open access · hybridAbstract read
In one paragraph

Article in British journal of cancer, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
5.2field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 45 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Synthesis of [Molecules (Basel, Switzerland) · 2020
    Article
  5. Article
  6. Article
  7. Article
  8. Single-Cell Characterization of 18F-FLT Uptake with Radioluminescence Microscopy.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2016
    Article
  9. Assessment of tumor response to chemotherapy in patients with breast cancer using (18)F-FLT: a meta-analysis.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2014
    Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Current molecular imaging positron emitting radiotracers in oncology.Nuclear medicine and molecular imaging · 2011
    Review
  18. Article
  19. Article
  20. Radiopharmaceuticals in preclinical and clinical development for monitoring of therapy with PET.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2009
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

W G E DirecksDepartment of Nuclear Medicine & PET Research, VU University Medical Centre, P.O. Box 7057, 1007 MB Amsterdam, The Netherlands.
S C Berndsen
N Proost
G J Peters
J Balzarini
M D Spreeuwenberg
A A Lammertsma
C F M Molthoff
Amsterdam UMC Location VUmc · NLKU Leuven · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Increased 2'-deoxy-2'-[18F]fluoro-D-glucose (FDG) uptake is the most commonly used marker for positron emission tomography in oncology. However, a proliferation tracer such as 3'-deoxy-3'-[18F]fluorothymidine (FLT) might be more specific for cancer. 3'-deoxy-3'-[18F]fluorothymidine uptake is dependent on thymidine kinase 1 (TK) activity, but the effects of chemotherapeutic agents are unknown. The aim of this study was to characterise FDG and FLT uptake mechanisms in vitro before and after exposure to chemotherapeutic agents. The effects of 5-fluorouracil (5-FU), doxorubicin and paclitaxel on FDG and FLT uptake were measured in MDA MB231 human breast cancer cells in relation to cell cycle distribution, expression and enzyme activity of TK-1. At IC50 concentrations, 5-FU resulted in accumulation in the G1 phase, but doxorubicin and paclitaxel induced a G2/M accumulation. Compared with untreated cells, 5-FU and doxorubicin increased TK-1 levels by >300. At 72 h, 5-FU decreased FDG uptake by 50% and FLT uptake by 54%, whereas doxorubicin increased FDG and FLT uptake by 71 and 173%, respectively. Paclitaxel increased FDG uptake with >100% after 48 h, whereas FLT uptake hardly changed. In conclusion, various chemotherapeutic agents, commonly used in the treatment of breast cancer, have different effects on the time course of uptake of both FDG and FLT in vitro. This might have implications for interpretation of clinical findings.

Indexed as

Antineoplastic AgentsBreast NeoplasmsCell CycleCell Line, TumorDoxorubicinFluorodeoxyglucose F18FluorouracilHumansPaclitaxelThymidineThymidine KinaseAntineoplastic AgentsDoxorubicinFluorodeoxyglucose F18FluorouracilPaclitaxelThymidineThymidine Kinase

Identifiers

PMID18665170
PMCPMC2527810
OpenAlexW2094589876

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.